Smart Factories with IDMO Model Proposed to Standardize Global Cell and Gene Therapy Manufacturing

A new approach to addressing manufacturing challenges in the cell and gene therapy (CGT) sector emphasizes the use of smart factories equipped with fully automated platforms. Industry experts highlight that global scalability in CGT production requires standardized, replicable processes that function consistently across different locations. This strategy aims to overcome bottlenecks in manufacturing by leveraging advanced technologies associated with Industry 4.0.

The proposed solution involves implementing the IDMO model, which integrates automation and digitalization into manufacturing workflows. By adopting this model, facilities can streamline operations and ensure uniformity in production methods regardless of geographical location. The approach aligns with broader efforts to modernize pharmaceutical manufacturing through innovative technologies, enabling more efficient scaling of CGT therapies worldwide.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 28, 2025

Related posts:

FDA Staffing Cuts Force Biotech Firms to Postpone Clinical Trials and Drug Testing Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug Healthcare Professionals Adapt to Expanded Roles: Managing Inventory Fluctuations and Advising on Alternative Therapies Mixed results: Study finds potential link between infant acid-suppressants and celiac disease

Author

Mark Chiang